Beyond the Horizon: The Promise of Novel Therapies for Relapsed/Refractory DLBCL
Nathan H. Fowler, MD
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Jia Ruan, MD, PhD
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, NY
Stephanie Larson, PhD
Clinical Content Manager
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Edward Allan Racela Sison, MD
Missouri City, TX
Upon completion, participants should be able to:
- Describe the mechanisms of action of emerging treatment strategies in relapsed/refractory DLBCL and discuss the available efficacy and safety data for these therapies
- Incorporate available data about novel therapies in clinical development for relapsed/refractory DLBCL into treatment decisions
This activity is intended for hematologists and oncologists.
Statement of Need
DLBCL is the most common type of non-Hodgkin lymphoma (NHL), accounting for almost 40% of all NHL cases. Approximately 5.5 cases per 100,000 people are diagnosed annually, and approximately 1.8 per 100,000 people will die of the disease this year. DLBCL is an aggressive cancer of B lymphocytes that confers a survival prognosis of less than 1 year in untreated patients. With treatment, more than 60% of patients with DLBCL survive at least 5 years after their diagnosis. However, approximately 10% of patients are refractory to treatment, and 30% to 40% of patients relapse, demonstrating the need for additional therapies in DLBCL as well as education to support clinician awareness of emerging DLBCL treatment strategies.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: April 30, 2019
Expiration Date: April 29, 2020
Estimated Time to Complete This Activity: 30 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Nathan H. Fowler, MD
Consulting fees/advisory boards: AbbVie, Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., TG Therapeutics
Contracted research: AbbVie, Inc., Celgene Corporation, F. Hoffman-La Roche Ltd.
Jia Ruan, MD, PhD
Consulting fees/advisory boards: AstraZeneca, Celgene Corporation, Seattle Genetics
Contracted research: Celgene Corporation, Pharmacyclics LLC, Seattle Genetics
Edward Allan Racela Sison, MD
Salary: Covance, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Laboratory Corporation of America, United Health Group Inc.
The peer reviewers and other activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.